BlaidsX Neuro vs Otofonix Groove

The BlaidsX Neuro is a mid-priced behind-the-ear OTC hearing aid priced at $799, earning a B grade with a SoundScore of 3.4/5 in our lab testing. This places it in the top 68% of OTC hearing aids tested, though it falls below the category average of 3.71. In our testing, the BlaidsX Neuro showed notable strengths in speech clarity for quiet environments, scoring 0.54 points above the category average. Feedback handling was excellent at 5.0/5, ranking among the best we've measured and 0.46 points above average. These results suggest the device may work well for conversations in calm settings where background noise isn't a factor. However, the device showed significant limitations in other areas. Speech in noise performance scored low at 1.0/5, falling 0.48 points below the category average—a concern for users who need help in challenging listening environments. Own-voice comfort also scored below average at 1.7/5, and music streaming scored 0.0/5, making it unsuitable for those who want to stream audio content. At this price point, buyers face strong competition. Devices like the Sony CRE-E10 and Lexie B2 Plus offer substantially higher overall scores in the same price range. The BlaidsX Neuro may suit users who primarily need help with face-to-face conversation in quiet spaces and don't require streaming capabilities, but those seeking versatile performance should consider alternatives.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE device ranks 36th out of 36 tested prescription hearing aids, placing it in the bottom tier of its category. In our testing, the Groove demonstrated one clear strength: excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. The device remained stable during our standardized challenge motions with no audible feedback issues. However, speech performance was significantly limited, with both speech in quiet and speech in noise scoring 1.0/5—falling 2.32 and 0.96 points below their respective category averages. Music streaming quality scored 0.0/5, which is 2.64 points below the prescription category average. Own-voice comfort was also low at 0.4/5 in the tuned configuration, 2.35 points below average, suggesting notable occlusion-related concerns. The normalized Initial Score of 2.7/5 and Tuned Score of 2.6/5 indicate that professional fitting adjustments did not improve overall performance. Given its positioning at the bottom of the prescription hearing aid category and the availability of lower-priced alternatives that scored higher in our testing, the Otofonix Groove may be difficult to recommend for most users seeking balanced sound quality across listening situations.